Compare Biogen Inc (BIIB) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Redwire Corporation — how do they compare? Biogen Inc trades at $191.1 (market cap $28.34B), while Redwire Corporation trades at $10.12 (market cap $2.33B). The key difference: Biogen Inc is far larger — about 12.2× Redwire Corporation's market cap, and Biogen Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| BIIB | RDW | |
|---|---|---|
Market Cap | $28.34B | $2.33B |
Sector | Health | Technology |
52-Week High | $216.63 | $25.90 |
52-Week Low | $122.68 | $5.06 |
Enterprise Value | $30.62B | $2.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
RDW trades at $9.59, down 5.8% with bearish technical signals despite 80% analyst buy ratings. The company shows significant revenue growth but deep losses, with net income margin at -80.9% and negative cash flow from operations. Recent news highlights dilution concerns from a $500M stock offering and competitive pressure from SpaceX's market dominance.
The stock presents high-risk potential with analyst consensus target of $19.00 representing 98% upside, but requires improved profitability and reduced cash burn. Key risks include persistent losses, dilution from financing activities, and intense space sector competition that could limit near-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
